The subcommittee will come to order without objection the chair is authorized a recess at any time this hearing examines the federal response to youth cigarette use and fda compliance policy. I now recognize myself for five minutes for an Opening Statement. September 11 this year the administration released disturbing results and at the vaping epidemic continues to grow to alltime highs. And that they use ecigarettes the trends are alarming for High School Students and to show you two visuals in 201712 percent were vaping and a 2019 almost 20 percent that 135 percent increase among High Schoolers. On your left is another visual which is more disturbing in 2173. 3 percent of middle schoolers were vaping today its almost 11 percent 218 percent rise in vaping among middle schoolers and as a parent of three children the statistics are extremely disturbing the data also shows that flavors are driving youth vaping 72 percent whove ate use flavors they use meant or mental which is the most po
The subcommittee will come to order without objection the chair is authorized a recess at any time this hearing examines the federal response to youth cigarette use and fda compliance policy. I now recognize myself for five minutes for an Opening Statement. September 11 this year the administration released disturbing results and at the vaping epidemic continues to grow to alltime highs. And that they use ecigarettes the trends are alarming for High School Students and to show you two visuals in 201712 percent were vaping and a 2019 almost 20 percent that 135 percent increase among High Schoolers. On your left is another visual which is more disturbing in 2173. 3 percent of middle schoolers were vaping today its almost 11 percent 218 percent rise in vaping among middle schoolers and as a parent of three children the statistics are extremely disturbing the data also shows that flavors are driving youth vaping 72 percent whove ate use flavors they use meant or mental which is the most po
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So
September 2019 but not yet implemented. [inaudible conversations] the subcommittee will come to order without objection the chair is authorized a recess at any time this hearing examines the federal response to youth cigarette use and fda compliance policy. I now recognize myself for five minutes for an Opening Statement. September 11 this year the administration released disturbing results and at the vaping epidemic continues to grow to alltime highs. And that they use ecigarettes the trends are alarming for High School Students and to show you two visuals in 201712 percent were vaping and a 2019 almost 20 percent that 135 percent increase among High Schoolers. On your left is another visual which is more disturbing in 2173. 3 percent of middle schoolers were vaping today its almost 11 percent 218 percent rise in vaping among middle schoolers and as a parent of three children the statistics are extremely disturbing the data also shows that flavors are driving youth vaping 72 percent w
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So